{"schema_version":"secwatch.filing_event.v1","accession":"0001804220-22-000020","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.376418+00:00","generated_at":"2026-06-24T05:34:27.080600+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Regeneron Q2 revenue down 44% to $2.86B; core revenue up 20%; EPS $7.47 GAAP, $9.77 non-GAAP","bullets":["Excluding REGEN-COV, total revenue grew 20% to $2.849B, driven by EYLEA ($1.62B +14%) and Dupixent ($2.09B +40%).","GAAP net income $852M ($7.47 diluted EPS) vs $3.099B ($27.97) Q2 2021; non-GAAP EPS $9.77 vs $25.80.","Acquired Checkmate Pharmaceuticals for ~$250M and purchased Sanofi's Libtayo worldwide rights for $900M up-front.","FDA approved Dupixent for atopic dermatitis in children 6 months-5 years and eosinophilic esophagitis; priority review for prurigo nodularis.","Updated 2022 guidance: R&D $3.485-3.655B GAAP; SG&A $1.99-2.11B; gross margin on net product sales 90-91%."],"urls":{"canonical":"https://secwatch.observer/filing/0001804220-22-000020","json":"https://secwatch.observer/filing/0001804220-22-000020.json","markdown":"https://secwatch.observer/filing/0001804220-22-000020.md","text":"https://secwatch.observer/filing/0001804220-22-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000180422022000020/0001804220-22-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000180422022000020/regn-20220803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:34:27.080600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}